中國中藥(00570.HK)以受讓股權方式投資甘肅隴中藥業
格隆匯12月31日丨中國中藥(00570.HK)公告,於2019年12月30日與甘肅隴中藥業有限責任公司股東甘肅省中醫院簽署投資協議,以人民幣1.39億元的價格受讓甘肅省中醫院所持有的隴中藥業51%股權。股權交割完成後廣東一方將持有隴中藥業51%的股權,甘肅省中醫院將持有隴中藥業35%的股權,甘肅藥業投資集團有限公司將持有隴中藥業14%的股權。
甘肅省是我國重點藥材產地及集散地,是創建國家中醫藥產業發展綜合試驗區,是中醫藥企業重點投資的地區一,在中醫藥產業發展方面有良好的政策支持和市場氛圍。隴中藥業是甘肅省中醫院對其科研製劑中心實現公司化改制、市場化經營而成立的公司,主要從事醫院製劑、中藥飲片等業務。
收購隴中藥業,實現院企合作,一方面有助於本集團快速切入發展前景廣闊的醫院製劑領域,另一方面進一步加強本集團中藥配方顆粒、中成藥、中藥飲片在當地市場的競爭優勢,實現本集團在甘肅地區的中藥全產業鏈佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.